MAR 28, 2019 5:35 PM PDT

Big Pharma to Take Another Look at Marijuana

WRITTEN BY: Amy Loriaux

Ever since the FDA approved the first drug derived from cannabis last year pharmaceutical companies big and small are taking another look at the plant for therapeutic potential. According to an article published on the website axios.com by Sam Baker, scientists are looking at cannabis - and psychedelics - as potential avenues towards profitable new medications. This is due, at least in part, to the relaxing of opinions regarding marijuana use, especially for medical purposes, around the country. The interest in psychedelics comes from the latest results from drugs such as ketamine, which has been shown to provide quick relief from depressive symptoms.

Photo source: UnSplash.com

According to another article published on the website globalnews.ca by Laura Hensley, marijuana may be becoming "the new Oxycontin". Two years ago at the Family Medical Forum in 2017, the largest family medicine conference in Canada, medical marijuana companies lined the exhibitor's hall. They tried to convince attendees to take a look at their wares, promising treatments for "this and that", according to one physician who attended, a Dr. Sarah Giles. She continued to say that, "none of [these claims] was evidence-based" and that “Marijuana is the next OxyContin, where everyone’s like, ‘Oh, it’s not addictive, it’s harmless, it’s good,’ and people are kind of using it willy-nilly because you can get it prescribed and not prescribed.”

Part of this hesitation towards medical marijuana comes from the fact that it is still not being taught in medical school. Furthermore, doctors tend to perceive a lack of evidence that it’s an effective treatment for things like pain, sleep disorders and anxiety. There are also concerns around dosing. Big Pharma companies could actually change that perception, as they do with all of their products. They hire sales representatives and medical science liaisons to provide educational materials and answer questions from clinicians regarding their latest pills.

A few of the pharmaceutical companies interested in the medical marijuana market include Novartis subsidiary Sandoz, which has partnered with the Canadian marijuana company Tilray; GW Pharmaceuticals, who released the FDA-approved cannabis-derivative Epidiolex; and AbbVie, which is exploring cannabis medicine and what products can be derived from it. 

Will medical marijuana start to appear on the shelves? Photo source: UnSplash.com

Even pharmacies are getting into the act. According to an article on CNBC.com, Walgreens is planning to sell cannabidiol (CBD) creams, patches, and sprays in nearly 1,500 stores in select states. CVS introduced CBD-containing topicals, including creams and salves, to stores in eight states earlier in March. Mind you, CBDs are not quite "medical marijuana" in the strictest sense, but it does highlight an interesting trend that is moving into our drugstores. According to Brian Sterz, portfolio manager of Miracle Mile Advisors, a private financial firm, "There's too much revenue to be made by states and the federal government (to not allow) cannabis-related drugs and products to become available."

While medical marijuana is still in its infancy, and the potential medical uses of marijuana still being elucidated, this dive into the market may seem to be premature. However, sometimes you have to capitalize on the market and not the science. Hopefully, these pharmaceutical companies can make extraordinary drugs from the cannabis plant, and not lead us into another "opioid-style" epidemic. 

See the video below for more details.

Video source: YouTube.com

Source: LabRoots.com, www.axios.com, The Independent Institute, GlobalNews.ca, Medical Science Liaison Society, the-scientist.com, investigators.com, cnbc.com

 

About the Author
  • I currently work at a small CRO involved in clinical trial management.
You May Also Like
AUG 16, 2019
Health & Medicine
AUG 16, 2019
Gene Linked To Cannabis Abuse
Research shows that there may be a specific gene associated with a higher risk of cannabis abuse. The same gene is responsible for the so-called nicotine r...
OCT 09, 2019
Cannabis Sciences
OCT 09, 2019
Cannabidiol's Role in Psychiatry
How can health professionals in the clinical psychiatry field make sense of cannabis products boasting various health claims? One professor’s present...
OCT 11, 2019
Health & Medicine
OCT 11, 2019
Medical Marijuana Allowed in California K-12 Schools
Gavin Newson, the governor of California and the leading 2016 proponent of the recreational pot legalization initiative Proposition 64, signed a bill on We...
DEC 10, 2019
Cannabis Sciences
DEC 10, 2019
Increased Cannabis Use Associated with Depression in U.S.
More than 700,000 people ages 12 and older responded to a survey assessing cannabis use, depressive status, and perceptions of risk associated with cannabi...
FEB 10, 2020
Cannabis Sciences
FEB 10, 2020
Colorado State University Launches Major in Cannabis Sciences
Colorado was one of the first two states in the US, together with Washington, to legalize recreational marijuana in 2012. Now, starting from fall this year...
FEB 19, 2020
Cannabis Sciences
FEB 19, 2020
Is it Better to Eat or Smoke Cannabis?
Smoking is well-known as a bad health habit. Although not necessarily as detrimental as smoking cigarettes, smoking cannabis is nevertheless  known to...
Loading Comments...